Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences ... - Stock Titan

Summary

The article describes Enzolytics, Inc.'s three-year research agreement with the Bulgarian Academy of Sciences to develop cancer treatments using Monoclonal Antibodies and Immune Therapeutic Proteins. Key concepts like 'epidemiology' relate to their shared focus on infectious diseases. Tags such as 'Spanish,' are seemingly unrelated but 'Bulgaria' reflects the regional aspect of the research partnership.